Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron
CEO, Mike Lampron
Source: Mach7 Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mach7 Technologies (M7T) receives new orders from existing customers Trinity Health and Penn State Milton S. Hershey Medical Centre
  • Trinity Health has signed a statement of work that surrounds the first deployment wave of its Unified Clinical Imaging Platform
  • This will see Mach7’s Enterprise Imaging Platform, Universal Worklist, eUnity Enterprise viewer and eUnity Diagnostic View implemented at Trinity’s facilities across Michigan
  • Additionally, Penn State has signed a contract renewal and licence expansions for the Mach7 Enterprise Engineering Platform
  • Mach7 ends the day a slight 0.68 per cent in the green with shares trading at 74 cents

Mach7 Technologies (M7T) has received new orders from existing customers Trinity Health and Penn State Milton S. Hershey Medical Centre.

Trinity Health has signed a statement of work that surrounds the first deployment wave of its Unified Clinical Imaging Platform.

This platform will see Mach7’s Enterprise Imaging Platform, Universal Worklist, eUnity Enterprise viewer and eUnity Diagnostic View implemented at Trinity’s facilities across southeast Michigan.

The statement of work has a total contract value of $900,000 which Mach7 will recognise as services revenue from now until FY23.

The devices will be deployed in waves and once all waves have been fully deployed, Mach7’s solution will be available across 92 hospitals in 22 states.

Penn State has signed a contract renewal and licence expansions for the Mach7 Enterprise Engineering Platform.

The renewal has a two-year term and will cover 575,000 procedures annually while the expansions include one for increase volumes at Penn State’s current site and the other to expand to a new site.

The total contract value comes to $1.5 million of which $1.1 million is capital software revenue to be recognised in FY22 and $400,000 in support revenue to be recognised from now until March 2023.

“I am pleased to see continued adoption and growth from our current customers. This is a testament to the value of our products and the strength of our relationships,” CEO Mike Lampron said.

“The Mach7 solution will provide a strong core to Trinity Health’s Unified Clinical Imaging
Platform Strategy, and Penn State has used Mach7 for years to handle large volumes of imaging procedures.”

Mach7 has ended the day a slight 0.68 per cent in the green with shares trading at 74 cents in a $175.1 million market cap.

M7T by the numbers
More From The Market Online
FDA HQ

Neurotech bounces back from FDA rejection with new baseline study for NTI164

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching…
Rio de Janeiro

Equinox sniffs shallow and high-grade titanium ahead of MRE for Brazilian play

Equinox Resources Ltd has picked up a suite of strong results in titanium oxide and total…
Vietnam flag

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

TruScreen Group (ASX:TRU) has opted to launch a five-year cervical cancer screening run in Vietnam's Ho…
An underground gold mine

New zones of high-grade gold impress Antipa at Minyari

A program of RC drilling has pulled up results showing multiple zones of high-grade gold in…